Aziz Zaanan1,2,3, Qian Shi4, Julien Taieb2,3, Steven R Alberts5, Jeffrey P Meyers4, Thomas C Smyrk6, Catherine Julie7,8, Ayman Zawadi9, Josep Tabernero10, Enrico Mini11, Richard M Goldberg12, Gunnar Folprecht13, Jean Luc Van Laethem14, Karine Le Malicot15, Daniel J Sargent4, Pierre Laurent-Puig2,16,17, Frank A Sinicrope1. 1. Departments of Medicine and Oncology, Mayo Clinic and Mayo Comprehensive Cancer Center, Rochester, Minnesota. 2. Paris Descartes University, Sorbonne Paris Cité, France. 3. Department of Gastroenterology and Digestive Oncology, European Georges Pompidou Hospital, APHP, Paris, France. 4. Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota. 5. Department of Oncology, Mayo Clinic, Rochester, Minnesota. 6. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. 7. Department of Pathology, Ambroise Paré Hospital, APHP, Boulogne-Billancourt, France. 8. Versailles Saint-Quentin-en-Yvelines University, Boulogne-Billancourt, France. 9. Radiotherapy Unit, Departemental Hospital Center, La Roche Sur Yon, France. 10. Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain. 11. Section of Internal Medicine, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. 12. Division of Medical Oncology, Ohio State University, Columbus. 13. First Medical Department, University Hospital Carl Gustav Carus, Dresden, Germany. 14. Department of Gastroenterology, Erasme Hospital University, Brussels, Belgium. 15. Department of Statistics, Fédération Francophone de Cancérologie Digestive, Dijon, France. 16. UMR-S 1147, INSERM, Paris, France. 17. Department of Biology, European Georges Pompidou Hospital, APHP, Paris, France.
Abstract
IMPORTANCE: The prognostic impact of DNA mismatch repair (MMR) status in stage III colon cancer patients receiving FOLFOX (folinic acid, fluorouracil, and oxaliplatin) adjuvant chemotherapy remains controversial. OBJECTIVE: To determine the association of MMR status with disease-free survival (DFS) in patients with stage III colon cancer treated with FOLFOX. DESIGN, SETTING, AND PARTICIPANTS: The evaluated biomarkers for MMR status were determined from prospectively collected tumor blocks from patients treated with FOLFOX in 2 open-label, phase 3 randomized clinical trials: NCCTG N0147 and PETACC8. The studies were conducted in general community practices, private practices, and institutional practices in the United States and Europe. All participants had stage III colon adenocarcinoma. They were enrolled in NCCTG N0147 from February 2004 to November 2009 and in PETACC8 from December 2005 to November 2009. INTERVENTIONS: Patients in the clinical trials were randomly assigned to receive 6 months of chemotherapy with FOLFOX or FOLFOX plus cetuximab. Only those patients treated with FOLFOX alone were included in the present study. MAIN OUTCOMES AND MEASURES: Association of MMR status with DFS was analyzed using a stratified Cox proportional hazards model. Multivariable models were adjusted for age, sex, tumor grade, pT/pN stage, tumor location, ECOG (Eastern Cooperative Oncology Group) performance status, and BRAF V600E mutational status. RESULTS: Among 2636 patients with stage III colon cancer treated with FOLFOX, MMR status was available for 2501. Of these, 252 (10.1%) showed deficient MMR status (dMMR; 134 women, 118 men; median age, 59 years), while 2249 (89.9%) showed proficient MMR status (pMMR; 1020 women, 1229 men; median age, 59 years). The 3-year DFS rates in the dMMR and pMMR groups were 75.6% and 74.4%, respectively. By multivariate analysis, patients with dMMR phenotype had significantly longer DFS than those with pMMR (adjusted hazard ratio, 0.73; 95% CI, 0.54-0.97; P = .03). CONCLUSIONS AND RELEVANCE: The deficient MMR phenotype remains a favorable prognostic factor in patients with stage III colon cancer receiving FOLFOX adjuvant chemotherapy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00079274 for the NCCTG N0147 trial and EudraCT identifier: 2005-003463-23 for the PETACC8 trial.
IMPORTANCE: The prognostic impact of DNA mismatch repair (MMR) status in stage III colon cancer patients receiving FOLFOX (folinic acid, fluorouracil, and oxaliplatin) adjuvant chemotherapy remains controversial. OBJECTIVE: To determine the association of MMR status with disease-free survival (DFS) in patients with stage III colon cancer treated with FOLFOX. DESIGN, SETTING, AND PARTICIPANTS: The evaluated biomarkers for MMR status were determined from prospectively collected tumor blocks from patients treated with FOLFOX in 2 open-label, phase 3 randomized clinical trials: NCCTG N0147 and PETACC8. The studies were conducted in general community practices, private practices, and institutional practices in the United States and Europe. All participants had stage III colon adenocarcinoma. They were enrolled in NCCTG N0147 from February 2004 to November 2009 and in PETACC8 from December 2005 to November 2009. INTERVENTIONS: Patients in the clinical trials were randomly assigned to receive 6 months of chemotherapy with FOLFOX or FOLFOX plus cetuximab. Only those patients treated with FOLFOX alone were included in the present study. MAIN OUTCOMES AND MEASURES: Association of MMR status with DFS was analyzed using a stratified Cox proportional hazards model. Multivariable models were adjusted for age, sex, tumor grade, pT/pN stage, tumor location, ECOG (Eastern Cooperative Oncology Group) performance status, and BRAF V600E mutational status. RESULTS: Among 2636 patients with stage III colon cancer treated with FOLFOX, MMR status was available for 2501. Of these, 252 (10.1%) showed deficient MMR status (dMMR; 134 women, 118 men; median age, 59 years), while 2249 (89.9%) showed proficient MMR status (pMMR; 1020 women, 1229 men; median age, 59 years). The 3-year DFS rates in the dMMR and pMMR groups were 75.6% and 74.4%, respectively. By multivariate analysis, patients with dMMR phenotype had significantly longer DFS than those with pMMR (adjusted hazard ratio, 0.73; 95% CI, 0.54-0.97; P = .03). CONCLUSIONS AND RELEVANCE: The deficient MMR phenotype remains a favorable prognostic factor in patients with stage III colon cancer receiving FOLFOX adjuvant chemotherapy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00079274 for the NCCTG N0147 trial and EudraCT identifier: 2005-003463-23 for the PETACC8 trial.
Authors: Frank A Sinicrope; Michelle R Mahoney; Thomas C Smyrk; Stephen N Thibodeau; Robert S Warren; Monica M Bertagnolli; Garth D Nelson; Richard M Goldberg; Daniel J Sargent; Steven R Alberts Journal: J Clin Oncol Date: 2013-09-09 Impact factor: 44.544
Authors: Julien Taieb; Josep Tabernero; Enrico Mini; Fabien Subtil; Gunnar Folprecht; Jean-Luc Van Laethem; Josef Thaler; John Bridgewater; Lone Nørgård Petersen; Hélène Blons; Laurence Collette; Eric Van Cutsem; Philippe Rougier; Ramon Salazar; Laurent Bedenne; Jean-François Emile; Pierre Laurent-Puig; Come Lepage Journal: Lancet Oncol Date: 2014-06-11 Impact factor: 41.316
Authors: Arnaud D Roth; Sabine Tejpar; Mauro Delorenzi; Pu Yan; Roberto Fiocca; Dirk Klingbiel; Daniel Dietrich; Bart Biesmans; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Laura Cisar; Roberto Labianca; David Cunningham; Eric Van Cutsem; Fred Bosman Journal: J Clin Oncol Date: 2009-12-14 Impact factor: 44.544
Authors: A Zaanan; P Cuilliere-Dartigues; A Guilloux; Y Parc; C Louvet; A de Gramont; E Tiret; S Dumont; B Gayet; P Validire; J-F Fléjou; A Duval; F Praz Journal: Ann Oncol Date: 2009-10-15 Impact factor: 32.976
Authors: Patrick G Gavin; Linda H Colangelo; Debora Fumagalli; Noriko Tanaka; Matthew Y Remillard; Greg Yothers; Chungyeul Kim; Yusuke Taniyama; Seung Il Kim; Hyun Joo Choi; Nicole L Blackmon; Corey Lipchik; Nicholas J Petrelli; Michael J O'Connell; Norman Wolmark; Soonmyung Paik; Kay L Pogue-Geile Journal: Clin Cancer Res Date: 2012-10-08 Impact factor: 12.531
Authors: C Guillén-Ponce; E Lastra; I Lorenzo-Lorenzo; T Martín Gómez; R Morales Chamorro; A B Sánchez-Heras; R Serrano; M C Soriano Rodríguez; J L Soto; L Robles Journal: Clin Transl Oncol Date: 2020-01-24 Impact factor: 3.405
Authors: D M Le; S Ahmed; S Ahmed; B Brunet; J Davies; C Doll; M Ferguson; N Ginther; V Gordon; T Hamilton; P Hebbard; R Helewa; C A Kim; R Lee-Ying; H Lim; J M Loree; J P McGhie; K Mulder; J Park; D Renouf; R P W Wong; A Zaidi; T Asif Journal: Curr Oncol Date: 2019-12-01 Impact factor: 3.677